These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39236556)

  • 1. Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study.
    Kenny A; van Duijn J; Dintwe O; Heptinstall J; Burnham R; Sawant S; Zhang L; Mielke D; Khuzwayo S; Omar FL; Stanfield-Oakley S; Keyes T; Dunn B; Goodman D; Fong Y; Benkeser D; Zou R; Hural J; Hyrien O; Juraska M; Luedtke A; van der Laan L; Giorgi EE; Magaret C; Carpp LN; Pattacini L; van de Kerkhof T; Korber B; Willems W; Fisher LH; Schuitemaker H; Swann E; Kublin JG; Pau MG; Buchbinder S; Tomaka F; Nijs S; Lavreys L; Gelderblom HC; Corey L; Mngadi K; Gray GE; Borducchi E; Hendriks J; Seaton KE; Zolla-Pazner S; Barouch DH; Ferrari G; De Rosa SC; McElrath MJ; Andersen-Nissen E; Stieh DJ; Tomaras GD; Gilbert PB;
    EBioMedicine; 2024 Oct; 108():105320. PubMed ID: 39236556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
    Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
    Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.
    Zhao LP; Fiore-Gartland A; Carpp LN; Cohen KW; Rouphael N; Fleurs L; Dintwe O; Zhao M; Moodie Z; Fong Y; Garrett N; Huang Y; Innes C; Janes HE; Lazarus E; Michael NL; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Robb ML; De Rosa SC; Corey L; Gray GE; Seaton KE; Yates NL; McElrath MJ; Frahm N; Tomaras GD; Gilbert PB
    PLoS One; 2020; 15(1):e0226803. PubMed ID: 31999736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
    Laher F; Moodie Z; Cohen KW; Grunenberg N; Bekker LG; Allen M; Frahm N; Yates NL; Morris L; Malahleha M; Mngadi K; Daniels B; Innes C; Saunders K; Grant S; Yu C; Gilbert PB; Phogat S; DiazGranados CA; Koutsoukos M; Van Der Meeren O; Bentley C; Mkhize NN; Pensiero MN; Mehra VL; Kublin JG; Corey L; Montefiori DC; Gray GE; McElrath MJ; Tomaras GD
    PLoS Med; 2020 Feb; 17(2):e1003038. PubMed ID: 32092060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
    Moodie Z; Walsh SR; Laher F; Maganga L; Herce ME; Naidoo S; Hosseinipour MC; Innes C; Bekker LG; Grunenberg N; Mann P; Yu C; deCamp AC; Miner MD; Yates NL; Heptinstall J; Mkhize NN; Dintwe O; Frahm N; Cohen KW; Allen M; Hutter J; Wagner R; Pantaleo G; McElrath MJ; Tomaras GD; Morris L; Montefiori DC; Andersen-Nissen E; Gray GE; Gilbert PB; Kublin JG;
    PLoS Med; 2020 May; 17(5):e1003117. PubMed ID: 32442195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.
    Gray GE; Mngadi K; Lavreys L; Nijs S; Gilbert PB; Hural J; Hyrien O; Juraska M; Luedtke A; Mann P; McElrath MJ; Odhiambo JA; Stieh DJ; van Duijn J; Takalani AN; Willems W; Tapley A; Tomaras GD; Van Hoof J; Schuitemaker H; Swann E; Barouch DH; Kublin JG; Corey L; Pau MG; Buchbinder S; Tomaka F;
    Lancet Infect Dis; 2024 Nov; 24(11):1201-1212. PubMed ID: 39038477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
    Barouch DH; Tomaka FL; Wegmann F; Stieh DJ; Alter G; Robb ML; Michael NL; Peter L; Nkolola JP; Borducchi EN; Chandrashekar A; Jetton D; Stephenson KE; Li W; Korber B; Tomaras GD; Montefiori DC; Gray G; Frahm N; McElrath MJ; Baden L; Johnson J; Hutter J; Swann E; Karita E; Kibuuka H; Mpendo J; Garrett N; Mngadi K; Chinyenze K; Priddy F; Lazarus E; Laher F; Nitayapan S; Pitisuttithum P; Bart S; Campbell T; Feldman R; Lucksinger G; Borremans C; Callewaert K; Roten R; Sadoff J; Scheppler L; Weijtens M; Feddes-de Boer K; van Manen D; Vreugdenhil J; Zahn R; Lavreys L; Nijs S; Tolboom J; Hendriks J; Euler Z; Pau MG; Schuitemaker H
    Lancet; 2018 Jul; 392(10143):232-243. PubMed ID: 30047376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
    McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.
    Gray GE; Huang Y; Grunenberg N; Laher F; Roux S; Andersen-Nissen E; De Rosa SC; Flach B; Randhawa AK; Jensen R; Swann EM; Bekker LG; Innes C; Lazarus E; Morris L; Mkhize NN; Ferrari G; Montefiori DC; Shen X; Sawant S; Yates N; Hural J; Isaacs A; Phogat S; DiazGranados CA; Lee C; Sinangil F; Michael NL; Robb ML; Kublin JG; Gilbert PB; McElrath MJ; Tomaras GD; Corey L
    Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
    Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
    Baden LR; Stieh DJ; Sarnecki M; Walsh SR; Tomaras GD; Kublin JG; McElrath MJ; Alter G; Ferrari G; Montefiori D; Mann P; Nijs S; Callewaert K; Goepfert P; Edupuganti S; Karita E; Langedijk JP; Wegmann F; Corey L; Pau MG; Barouch DH; Schuitemaker H; Tomaka F;
    Lancet HIV; 2020 Oct; 7(10):e688-e698. PubMed ID: 33010242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk.
    Neidich SD; Fong Y; Li SS; Geraghty DE; Williamson BD; Young WC; Goodman D; Seaton KE; Shen X; Sawant S; Zhang L; deCamp AC; Blette BS; Shao M; Yates NL; Feely F; Pyo CW; Ferrari G; ; Frank I; Karuna ST; Swann EM; Mascola JR; Graham BS; Hammer SM; Sobieszczyk ME; Corey L; Janes HE; McElrath MJ; Gottardo R; Gilbert PB; Tomaras GD
    J Clin Invest; 2019 Nov; 129(11):4838-4849. PubMed ID: 31589165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
    Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.
    Malherbe DC; Wibmer CK; Nonyane M; Reed J; Sather DN; Spencer DA; Schuman JT; Guo B; Pandey S; Robins H; Park B; Fuller DH; Sacha JB; Moore PL; Hessell AJ; Haigwood NL
    Front Immunol; 2020; 11():984. PubMed ID: 32582155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US.
    Tieu HV; Karuna S; Huang Y; Sobieszczyk ME; Zheng H; Tomaras GD; Montefiori DC; Shen M; DeRosa S; Cohen K; Isaacs MB; Regenold S; Heptinstall J; Seaton KE; Sawant S; Furch B; Pensiero M; Corey L; Bar KJ;
    Vaccine; 2023 Oct; 41(42):6309-6317. PubMed ID: 37679276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.
    Zolla-Pazner S; deCamp A; Gilbert PB; Williams C; Yates NL; Williams WT; Howington R; Fong Y; Morris DE; Soderberg KA; Irene C; Reichman C; Pinter A; Parks R; Pitisuttithum P; Kaewkungwal J; Rerks-Ngarm S; Nitayaphan S; Andrews C; O'Connell RJ; Yang ZY; Nabel GJ; Kim JH; Michael NL; Montefiori DC; Liao HX; Haynes BF; Tomaras GD
    PLoS One; 2014; 9(2):e87572. PubMed ID: 24504509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01
    Van Der Meeren O; Jongert E; Seaton KE; Koutsoukos M; Aerssens A; Brackett C; Debois M; Janssens M; Leroux-Roels G; Mesia Vela D; Sawant S; Yates NL; Tomaras GD; Leroux-Roels I; Roman F
    Vaccine; 2020 Feb; 38(7):1678-1689. PubMed ID: 31932137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.